A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
The Districts of Germany (Kreise) are administrative districts, and every state except the city-states of Berlin and Hamburg and the state of Bremen consists of "rural districts" (Landkreise), District-free Towns/Cities (Kreisfreie Städte, in Baden-Württemberg also called "urban districts", or Stadtkreise), cities that are districts in their own right, or local associations of a special kind (Kommunalverbände besonderer Art), see below. The state Free Hanseatic City of Bremen consists of two urban districts, while Berlin and Hamburg are states and urban districts at the same time. As of 2011, there are 295 Landkreise and 107 Kreisfreie Städte, making 402 districts altogether. Each consists of an elected council and an executive, which is chosen either by the council or by the people, depending on the state, the duties of which are comparable to those of a county executive in the United States, supervising local government administration. The Landkreise have primary administrative functions in specific areas, such as highways, hospitals, and public utilities. Local associations of a special kind are an amalgamation of one or more Landkreise with one or more Kreisfreie Städte to form a replacement of the aforementioned administrative entities at the district level. They are intended to implement simplification of administration at that level. Typically, a district-free city or town and its urban hinterland are grouped into such an association, or Kommunalverband besonderer Art.
== Other poisonous plants == Many other plants not commonly used in food or drink are also poisonous, and care should be taken to avoid accidentally contacting or ingesting them. Some of these are popular ornamental plants or are cultivated for purposes other than consumption.
=== Anti-microbial function === Being highly motile, neutrophils quickly congregate at a focus of infection, attracted by cytokines expressed by activated endothelium, mast cells, and macrophages. Neutrophils express and release cytokines, which in turn amplify inflammatory reactions by several other cell types. In addition to recruiting and activating other cells of the immune system, neutrophils play a key role in the front-line defense against invading pathogens, and contain a broad range of proteins. Neutrophils have three methods for directly attacking microorganisms: phagocytosis (ingestion), degranulation (release of soluble anti-microbials), and generation of neutrophil extracellular traps (NETs).
Sources: en.wikipedia.org
The end result will thus be multiple organ failure [10] and damage to the muscles and nerves in the arms and legs. The animal trials done before the clinical trial had failed to predict this extreme species-selective toxicity. This is mainly due to that humans have the human equilibrate nucleoside transporter-1 (hENT-1) which will allow selective uptake of FIAU into the mitochondria in a way that other species do not.
Amitabha Chattopadhyay is an Indian scientist working in the areas of membrane and receptor biology and biophysics . He is presently a CSIR Bhatnagar Fellow at the Center for Cellular and Molecular Biology and served as the founding dean of biological sciences at the Academy of Scientific and Innovative Research (AcSIR). In addition, he is a distinguished visiting professor at the Indian Institute of Technology Bombay, adjunct professor at the Jawaharlal Nehru University (New Delhi), Tata Institute of Fundamental Research, Indian Institute of Science Education and Research (Kolkata), Swinburne University of Technology (Australia), and honorary professor at the Jawaharlal Nehru Centre for Advanced Scientific Research (Bangalore). He was elected a Fellow of the Royal Society of Chemistry in 2013 and Royal Society of Biology in 2017. Chattopadhyay has authored more than 300 research papers and has an h-index of 65. In 2016, Chattopadhyay won The World Academy of Sciences in Biology for his seminal contribution in understanding the role of membrane cholesterol in the organization and function in healthy and diseased conditions.
The discovery of the new elements and the new data on neutron capture were initially kept secret on the orders of the US military until 1955 due to Cold War tensions. Nevertheless, the Berkeley team were able to prepare einsteinium and fermium by civilian means, through the neutron bombardment of plutonium-239, and published this work in 1954 with the disclaimer that it was not the first studies that had been carried out on those elements. The "Ivy Mike" studies were declassified and published in 1955. The first significant (submicrogram) amounts of einsteinium were produced in 1961 by Cunningham and colleagues, but this has not been done for fermium yet. The first isotope of mendelevium, 256Md (half-life 87 min), was synthesized by Albert Ghiorso, Glenn T. Seaborg, Gregory Robert Choppin, Bernard G. Harvey and Stanley Gerald Thompson when they bombarded an 253Es target with alpha particles in the 60-inch cyclotron of Berkeley Radiation Laboratory; this was the first isotope of any element to be synthesized one atom at a time. There were several attempts to obtain isotopes of nobelium by Swedish (1957) and American (1958) groups, but the first reliable result was the synthesis of 256No by the Russian group of Georgy Flyorov in 1965, as acknowledged by the IUPAC in 1992. In their experiments, Flyorov et al. bombarded uranium-238 with neon-22. In 1961, Ghiorso et al. obtained the first isotope of lawrencium by irradiating californium (mostly californium-252) with boron-10 and boron-11 ions.
Sources: en.wikipedia.org
The 5 body regions are right upper, left upper, right lower, left lower, and axial. The Widespread Pain Index (WPI) was introduced by the American College of Rheumatology in 2010. It measures the number of body regions experiencing pain, out of a total of 19: left and right shoulder girdle, upper arm, lower arm, hip/buttock/trochanter, upper leg, lower leg, and jaw; plus the chest, abdomen, neck, upper back and lower back. The Symptom Severity Scale (SSS) assesses the severity of six symptoms; fatigue (score 0-3, for no problem, mild, moderate and severe), trouble thinking or remembering (0-3), waking up tired (unrefreshed) (0-3), pain or cramps in lower abdomen (0-1), depression (0-1) and headache (0-1). As of 2022, among diagnosis methods in the US, the ACR 2016 criteria have been judged as the best FM diagnosis criteria available. The UK RCP also recommends these criteria for FM diagnosis. A similar diagnostic approach is taken in Germany.In 2019, the American Pain Society in collaboration with the U.S. Food and Drug Administration developed a new diagnostic system using two dimensions. The first dimension included core diagnostic criteria, and the second included common features. The core diagnostic criteria are:
RNH2 + [CH3SC(NH2)2]+X− → [RN(H)C(NH2)2]+X− + CH3SH The resulting guanidinium ions can often be deprotonated to give the guanidine. This approach is sometimes called the Rathke synthesis, in honor of its discoverer Bernhard Rathke.
=== Exercise and fatigue === A low-carbohydrate diet has been found to reduce endurance capacity for intense exercise efforts, and depleted muscle glycogen following such efforts is only slowly replenished if a low-carbohydrate diet is taken. Inadequate carbohydrate intake during athletic training causes metabolic acidosis, which may be responsible for the impaired performance which has been observed.
A lymph node is divided into compartments called nodules (or lobules), each consisting of a region of cortex with combined follicle B cells, a paracortex of T cells, and a part of the nodule in the medulla. The substance of a lymph node is divided into the outer cortex and the inner medulla. The cortex of a lymph node is the outer portion of the node, underneath the capsule and the subcapsular sinus. It has an outer part and a deeper part known as the paracortex. The outer cortex consists of groups of mainly inactivated B cells called follicles. When activated, these may develop into what is called a germinal center. The deeper paracortex mainly consists of the T cells. Here the T-cells mainly interact with dendritic cells, and the reticular network is dense. The medulla contains large blood vessels, sinuses and medullary cords that contain antibody-secreting plasma cells. There are fewer cells in the medulla. The medullary cords are cords of lymphatic tissue, and include plasma cells, macrophages, and B cells.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.